<DOC>
	<DOC>NCT00624286</DOC>
	<brief_summary>This study was designed to provide 12 weeks efficacy and safety data of the 150 μg once-daily (od) dose of indacaterol in chronic obstructive pulmonary disease (COPD).</brief_summary>
	<brief_title>Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD)</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases, Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
	<criteria>• Male or female patients aged 40 years or over with moderate to severe chronic obstructive pulmonary disease (COPD) plus 20 packyear smoking history Signed informed consent Postbronchodilator forced expiratory volume in 1 second )FEV1) ≥ 30% and &lt; 80% predicted FEV1/FVC (forced vital capacity) &lt; 70% Exclusion Criteria include: History of asthma Prior exposure to indacaterol Active cancer or history of cancer Patients with concomitant pulmonary disease Patients with diabetes Type I or uncontrolled diabetes Type II Patients with a history of long QT syndrome or whose QTc interval (Bazett's) measured at screening or randomization is prolonged Patients unable to successfully use a drypowder inhaler device or perform spirometry measurements Other protocoldefined inclusion/exclusion criteria applied to the study.</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>chronic obstructive pulmonary disease</keyword>
	<keyword>COPD</keyword>
	<keyword>indacaterol</keyword>
</DOC>